Endo International plc announced that it has entered into an agreement with its partner, BioDelivery Sciences International, Inc. (BDSI), to return the Belbuca (buprenorphine) buccal film product to BDSI. Specific financial terms of the agreement have not been disclosed and are not material to Endo. Endo will not have any future royalty or milestone payments to BDSI and BDSI is not obligated for any future royalty payments to Endo.